Objectives To describe patient characteristics, use of drug treatments, and quality of life on subjects in a Swedish patient registry database.
Methods A descriptive analysis using a Swedish patient registry collected in an outpatient clinic in the region of Göteborg from 1991 to 2009 (study period). Included subjects were referred to the clinic for DXA scan for bone mineral density (BMD) measurement and osteoporosis (OP) diagnosis. Subjects were invited for a follow-up DXA scan every 2 years if the prior scan showed low BMD/OP diagnosis. This study analyzed patients' current and previous OP treatments, fracture risk related to characteristics at enrollment, and Quality of life (QoL). QoL was collected post-2004 and measured by EQ-5D-3L covering dimensions of mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Current and previous OP treatments were reported among subjects diagnosed with OP at first visit. Means and standard deviation (SD) were reported for continuous measures; percentages were reported for categorical measures.
Results 9,312 subjects were enrolled in the registry, 91% were female, with average age of 64.1 [SD=11.8] years. Average weight and height were 66.1 [SD=20.6] kg and 161.4 [SD=22.3] cm, respectively. 23% of patients reported prior history of fracture > age 40, 35% had family history of fractures, 28% had back pain, and 33% were currently smokers. At the first visit, 35% (3,292) patients had a T-score (either hip or lumbar spine) ≤ -2.5 and 42% (3,897) between -1 and -2.5. 38.5% (3,587) were diagnosed with OP and 43% (4,031) with osteopenia. EQ-5D was available for 1,570 patients whose first visit was post-2004. The average scores were as follow: mobility: 1.37 [SD=0.49], self-care: 1.11 [SD=0.35], usual activities: 1.34 [SD=0.56], pain/discomfort: 1.91 [SD=0.60], and anxiety/depression: 1.52 [SD=0.57]. Among 2,101 diagnosed with OP at first visit and having ≥1 follow-up visit, 55% (1,146) received bisphosphonates (BIS) (alendronate, optinate, and etidronate), 12% (259) received non-BIS (raloxifene and teriparatide), 79% (1,651) received calcium+vitamin D, and 26% (542) received estrogen. Conclusion: This analysis provided an overview of the characteristics in a Swedish registry. In this Swedish population, more than 1/3 of subjects receiving DXA scan were diagnosed with OP or having T-score≤ -2.5; however, approximately one-third received no OP drug treatment (BIS or non-BIS) despite OP diagnosis.
Conclusions The Swedish patient registry presents opportunities to understand various unmet needs among OP patients as a result of extensive information collected overtime.
Disclosure of Interest A. Krishna Employee of: Merck & Co., Inc, D. Mellström Grant/research support: Merck & Co., Inc, Z. Li Consultant for: Merck & Co., Inc, C.-P. S. Fan Consultant for: Merck & Co., Inc, S. Salomonsson Employee of: Merck & Co., Inc, E. Waern Grant/research support: Merck & Co., Inc